The Biotechnology Industrialists’ Association (BİYOSAD) aims to drive human development via innovative, high value-added products and services and is establishing the Biotechnology Valley within the Biotechnology Specialized Industrial Zone (BİOSB) in Istanbul. This project aspires to situate Turkey among the world’s leading biotechnology hubs. Biotechnology Valley, positioned in strategically located Tuzla, Istanbul, is a comprehensive initiative designed to create a specialized biotechnology ecosystem. The project aims to boost Turkey’s global presence in the biotechnology market through strong collaborations between business, academia, and the government. It spans 2.7 million square meters and will feature technology development zones, R&D centers, testing and calibration labs, patent offices, and specialized biotechnology schools. Our goal is to enhance global export potential by fostering domestic production of high value-added biotechnology products. We prioritize guiding industry and academia toward innovative collaboration, exploring nature’s possibilities in light of science. Our mission extends beyond meeting current demands to making a positive impact for future generations through sustainable and collaborative efforts. Biotechnology Valley is dedicated to enabling breakthrough technologies in the sector and hosting research that benefits society, adding value to both science and business. We are committed to providing a safe, innovative, and supportive business environment for all sector stakeholders. Join us as a partner in transforming Türkiye and the world into a leading biotechnology center. | Biotechnology Valley is a strategic technology and innovation ecosystem established under the leadership of the Biotechnology Industrialists Association (BIYOSAD) to lead Türkiye’s vision in biotechnology across science, technology, and production. Bringing together the public sector, industry, academia, and investors, the Valley aims to build a high–value-added, sustainable, and globally competitive biotechnology infrastructure. Located in Tepeören, Istanbul, and spanning approximately 2.7 million square meters, Biotechnology Valley is one of Türkiye’s most comprehensive biotechnology initiatives. With its advanced R&D centers, technology development zones, modern manufacturing facilities, and shared infrastructure, the Valley is designed as an integrated hub for local and international companies operating in pharmaceuticals, biotechnology products, medical technologies, and advanced life sciences. Biotechnology Valley is not only a center for production and R&D, but also a living and innovation ecosystem with sustainability at its core. The project prioritizes energy-efficient infrastructure, renewable energy solutions, water efficiency practices, integrated waste management systems, and comprehensive strategies to reduce carbon footprint. This approach positions biotechnology production in harmony with nature and with a strong sense of responsibility toward future generations. The Valley offers a collaborative, innovative, and scalable ecosystem for a wide range of stakeholders, from start-ups and research institutions to global players and investment funds. Through its open innovation approach, Biotechnology Valley promotes knowledge sharing and co-creation, aiming to integrate Türkiye’s biotechnology potential into the global value chain. With its robust infrastructure, sustainability-driven framework, and international vision, Biotechnology Valley continues to advance with determination toward becoming a regional and global center for biotechnology.
Andelyn Biosciences
Our Vision: Pioneering Solutions that turn Hope into Reality Our Mission: Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 8+ production suites for customization of new programs and tech transferred programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO, analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing Andelyn Biosciences is a pioneering cell and gene therapy organization born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. See all our Press Releases at: https://www.andelynbio.com/media-center | Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions for Turning Hope into Reality (TM) as a gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. With 20+ years of experience in viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting and characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 450+ cGMP sublots, Andelyn provides research, tox, and GMP grade plasmids Andelyn also has full quality and regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility offers capacity across 16 production suites for customization of new programs as well as tech transfer programs, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Andelyn Biosciences is a pioneering gene therapy CDMO born out of Nationwide Children’s Hospital, where the first FDA-approved systemic gene therapy was discovered. | Andelyn Biosciences is a full-service cell and gene therapy CDMO focused on the development, characterization and production of viral vectors for gene therapy. With more than 20 years of experience, Andelyn’s deep scientific expertise has resulted in the production of cGMP material for more than 450 clinical batches and 75 global clinical trials. Operating out of its development and manufacturing facilities in Columbus, Ohio, Andelyn supports its clients in developing cell and gene therapies from concept through plasmid engineering and manufacturing, process and analytical development, and cGMP clinical and commercial manufacturing. Andelyn can accelerate programs and deliver high quality products by developing and manufacturing processes on its configurable, data-driven AAV CuratorTM Platform, or tech transferring in an established client program. Capabilities include cGMP manufacturing for suspension processes up to a 2,000-liter and adherent processes. A rigorous quality system, regulatory support, and supply chain vertical integration further support clients in bringing their critical therapies to market. For more information, visit andelynbio.com. For Andelyn media inquiries, please contact: media@andelynbiosciences.com
Agricultural Technology Research Institute
To strengthen the commercialization and industrialization of agricultural research results, the Council of Agriculture (COA) completed the preparatory works and established Agricultural Technology Research Institute (ATRI) on January 1, 2014. Under the ATRI there are Animal Technology Research Center, Plant Technology Research Center, Aquatic Technology Research Center, Business Promotion Center, and Agricultural Policy Research Center respectively in charge of related affairs. ATRI was formed by combining the following agencies: DPIAB – Development Program of Industrialization for Agricultural Biotechnology AgriTI – Office for Agricultural Technology Industry ATIT – Animal Technology Institute Taiwan COAT – Commercialization Office of Agricultural Technology Mission and Task To create a framework for the industrialization of agricultural technology and the development of entrepreneurship, provision of agricultural technology and commercialization/industrialization service to agribusiness, agricultural groups and farmers. 1.To work collaboratively with academia, other research institutes, and private sectors to develop innovative and useful technologies for commercial production. 2.To commercialize and industrialize agriculture research results. To provide assistances to private sectors in strengthening competitiveness and promoting international markets. 3.To serve as an intermediary platform for policy think-tanks. 4.To combine all efforts in promoting the common interests in agricultural area. Facilitations of decision-making process to provide solid foundation for agricultural policies in all forms. | x | To strengthen the commercialization and industrialization of agricultural research outcomes, the Ministry of Agriculture (MOA) completed the preparatory work and established the Agricultural Technology Research Institute (ATRI) on January 1, 2014. Under the ATRI there are Planning and Development Department, Administrative Services Department, Animal & Plant Health and Production Research Center, Agricultural Facilities and Environment Research Center, Agricultural Input and Product Valorization Research Center, Agricultural Policy Research Center and Industrial Development Center respectively in charge of related affairs. ATRI was formed by combining the following agencies: DPIAB – Development Program of Industrialization for Agricultural Biotechnology AgriTI – Office for Agricultural Technology Industry ATIT – Animal Technology Institute Taiwan COAT – Commercialization Office of Agricultural Technology
AB DigiHealth Inc.
AB DigiHealth Inc. stands as a pioneering, modern core laboratory dedicated to advancing genomic research. Originating as a startup from Center for Genomic Medicine, National Cheng Kung University in Taiwan, our mission is to bridge the gap between scientific discoveries and clinical applications, providing a comprehensive solution for maternal-fetal precision medicine to the world. Harnessing state-of-the-art Next-Generation Sequencing (NGS) technology, advanced bioinformatics, and AI predictive algorithms, our goal is to usher prenatal genetic testing into a new era. As guardians of maternal-fetal health, we endeavor to create an efficient, empowering digital solution that leverages cloud-based NGS analytics pipelines and AI-based companion diagnosis. Our vision is to establish a next-generation healthcare system characterized by high accuracy, enhancing operational efficiency in laboratories and clinics.